IFIsabel Fuentes-Calvo

Isabel Fuentes-Calvo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Isabel Fuentes-Calvo has a total of 112 co-authors. Here are the top co-authors by number of shared publications:

  • Jose Miguel Lopez-Novoa

    Unidad de Fisiopatología Renal y Cardiovascular, Instituto "Reina Sofía" de Investigación Nefrológica, Departamento de Fisiología y Farmacología, Universidad de Salamanca, Salamanca, Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain

    11 shared publications
  • Carlos Martínez-Salgado

    Translational Research on Renal and Cardiovascular Diseases (TRECARD), Department of Physiology and Pharmacology, Edificio Departamental, Campus Miguel de Unamuno, University of Salamanca, 37007 Salamanca, Spain

    8 shared publications
  • Carlos Martínez-Salgado

    5 shared publications
  • Eugenio Santos

    Centro de Investigación del Cáncer, Universidad de Salamanca, Consejo Superior de Investigaciones Científicas (CSIC), Salamanca, Spain

    5 shared publications
  • Fernando Pérez-Barriocanal

    Departamento de Fisiología y Farmacología, Universidad de Salamanca, Salamanca 37007, Spain Unidad de Fisiopatología Renal y Cardiovascular, Instituto 'Reina Sofía' de Investigación Nefrológica, Salamanca 37007, Spain Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca 37007, Spain

    3 shared publications
  • Francisco José López-Hernández

    Translational Research on Renal and Cardiovascular Diseases (TRECARD), Department of Physiology and Pharmacology, Edificio Departamental, Campus Miguel de Unamuno, University of Salamanca, 37007 Salamanca, Spain

    3 shared publications

Latest Publications

  • Open Access

    SUBCLINICAL ACUTE KIDNEY DISEASE: URINARY PROTEOMIC DIVERGENCE FOLLOWING NEPHROTOXIC AND ISCHAEMIC INJURY

    by Joana Mercado-Hernández, Isabel Fuentes-Calvo, David Martín-Calvo, Sandra M. Sancho-Martínez, Francisco J. López-Hernández, Carlos Martínez-Salgado

    Defective renal repair following acute kidney injury (AKI) may lead to acute kidney disease (AKD), defined by persistent functional and/or structural abnormalities lasting up to three months. However, subclinical AKD often goes undetected due to the lack of specific diagnostic tools, as conventional biomarkers such as plasma creatinine (pCr) may remain within normal limits despite underlying structural damage. To identify urinary proteomic signatures associated with subclinical AKD of differing etiologies, we induced AKI in Wistar rats using either toxic (cisplatin-induced) or ischemic (unilateral ischaemia-reperfusion, I/R) models, and monitored renal function, renal histopathology and urine composition over 42 days. Renal function, as assessed by pCr and creatinine clearance, was rapidly and severely impaired following treatment with cisplatin and I/R, and normalized afterwards within 10 and 2 days, respectively. Despite functional recovery, histological analysis revealed persistent tissue injury—characterized by tubular dilation, necrosis, inflammation, and interstitial fibrosis—particularly in cisplatin-treated animals at day 42. Urinary proteomic analysis identified 53 and 23 proteins that were differentially excreted with the urine in the cisplatin and I/R groups, respectively, compared to controls, and 11 proteins differed from one AKI etiology to the other. Additionally, 29 proteins appeared exclusively post-AKI, irrespective of cause. Most of these proteins are predominantly involved in the immune response, complement activation, haemostasis, and gluconeogenesis. These findings suggest that urinary proteomic fingerprints may serve as sensitive indicators of subclinical AKD, reflecting underlying structural damage even in the absence of overt functional impairment. Such profiles could offer etiology-specific insights, while also enabling the early detection of AKD across diverse injury contexts.

  • Valores de referencia de parámetros de rigidez arterial y su relación con los factores de riesgo cardiovascular en población española. Estudio EVA

    by Marta Gómez-Sánchez, M. Carmen Patino-Alonso, Leticia Gómez-Sánchez, José I. Recio-Rodríguez, Emiliano Rodríguez-Sánchez, José A. Maderuelo-Fernández, Luis García-Ortiz, Manuel A. Gómez-Marcos, Carlos Martínez-Salgado, Jesùs M. Hernández-Rivas, et al.


  • Urinary TCP1-eta: A Cortical Damage Marker for the Pathophysiological Diagnosis and Prognosis of Acute Kidney Injury

    by Sandra M Sancho-Martínez, Fernando Sánchez-Juanes, Víctor Blanco-Gozalo, Miguel Fontecha-Barriuso, Laura Prieto-García, Isabel Fuentes-Calvo, José M González-Buitrago, Ana I Morales, Carlos Martínez-Salgado, María A Ramos-Barron, et al.

    Acute kidney injury (AKI) is a serious syndrome with increasing incidence and health consequences, and high mortality rate among critically ill patients. Acute kidney injury lacks a unified definition, has ambiguous semantic boundaries, and relies on defective diagnosis. This, in part, is due to the absence of biomarkers substratifying AKI patients into pathophysiological categories based on which prognosis can be assigned and clinical treatment differentiated. For instance, AKI involving acute tubular necrosis (ATN) is expected to have a worse prognosis than prerenal, purely hemodynamic AKI. However, no biomarker has been unambiguously associated with tubular cell death or is able to provide etiological distinction. We used a cell-based system to identify TCP1-eta in the culture medium as a noninvasive marker of damaged renal tubular cells. In rat models of AKI, TCP1-eta was increased in the urine co-relating with renal cortical tubule damage. When kidneys from ATN rats were perfused in situ with Krebs-dextran solution, a portion of the urinary TCP1-eta protein content excreted into urine disappeared, and another portion remained within the urine. These results indicated that TCP1-eta was secreted by tubule cells and was not fully reabsorbed by the damaged tubules, both effects contributing to the increased urinary excretion. Urinary TCP1-eta is found in many etiologically heterogeneous AKI patients, and is statistically higher in patients partially recovered from severe AKI. In conclusion, urinary TCP1-eta poses a potential, substratifying biomarker of renal cortical damage associated with bad prognosis.


  • N -acetylcysteine transforms necrosis into apoptosis and affords tailored protection from cisplatin cytotoxicity

    by Sandra M. Sancho-Martínez, Laura Prieto-García, Marta Prieto, Isabel Fuentes-Calvo, José M. López-Novoa, Ana I. Morales, Carlos Martínez-Salgado, Francisco J. López-Hernández


  • Open Access

    Influence Of Angiogenic Mediators And Bone Remodelling In Paget´s Disease Of Bone

    by Isabel Fuentes-Calvo, Ricardo Usategui-Martín, Ismael Calero-Paniagua, Cristina Moledo-Pouso, Luis García-Ortiz, Javier Del Pino-Montes, Rogelio González-Sarmiento, Carlos Martínez-Salgado

    Paget´s disease of bone (PDB) is characterized by increased bone resorption followed by an excessive compensatory bone formation, with an abnormal bone structure with altered mechanical properties. Pagetic bone also has a higher vascularization and marrow fibrosis. Despite of pagetic bone being a highly vascularized tissue, there are no studies on the plasma levels of angiogenic mediators in the different states of the disease; moreover, the effect of PDB treatment on plasma levels of these angiogenic mediators is not very well known. The aim of this study was to analyse plasma levels of cytokines implicated in the increased bone turnover (OPG, RANKL, sclerostin) and hypervascularization (VEGF, PGF, ENG) observed in PDB and their evolution and response to zoledronic acid treatment in 70 PDB patients, 29 with an active disease measured by plasma alkaline phosphatase (ALP). Plasma ALP concentration was higher in active PDB than in inactive PDB patients, whereas there were no differences in OPG, RANKL, sclerostin, VEGF, PGF and ENG plasma levels between active and inactive PDB patients. ALP decreased at 3 and 12 months after zoledronic acid treatment. RANKL levels were reduced and sclerostin levels were increased after 12 months of treatment. PGF levels were lower 12 months after zoledronic acid treatment, whereas there were no differences in plasma VEGF and ENG after zoledronic acid treatment. Summarizing, zoledronic acid treatment is associated to decreases in plasma levels of ALP, RANKL, sclerostin and P1GF in active PDB patients. This treatment may reduce bone turnover and might reduce the pathological vascularisation typical of pagetic bone.


  • Absence of K‐Ras Reduces Proliferation and Migration But Increases Extracellular Matrix Synthesis in Fibroblasts

    by José M. Muñoz‐Félix, Isabel Fuentes‐Calvo, Cristina Cuesta, Nélida Eleno, Piero Crespo, José M. López‐Novoa, Carlos Martínez‐Salgado

    The involvement of Ras‐GTPases in the development of renal fibrosis has been addressed in the last decade. We have previously shown that H‐ and N‐Ras isoforms participate in the regulation of fibrosis. Herein, we assessed the role of K‐Ras in cellular processes involved in the development of fibrosis: proliferation, migration, and extracellular matrix (ECM) proteins synthesis. K‐Ras knockout (KO) mouse embryonic fibroblasts (K‐ras−/−) stimulated with transforming growth factor‐β1 (TGF‐β1) exhibited reduced proliferation and impaired mobility than wild‐type fibroblasts. Moreover, an increase on ECM production was observed in K‐Ras KO fibroblasts in basal conditions. The absence of K‐Ras was accompanied by reduced Ras activation and ERK phosphorylation, and increased AKT phosphorylation, but no differences were observed in TGF‐β1‐induced Smad signaling. The MEK inhibitor U0126 decreased cell proliferation independently of the presence of K‐ras but reduced migration and ECM proteins expression only in wild‐type fibroblasts, while the PI3K‐AKT inhibitor LY294002 decreased cell proliferation, migration, and ECM synthesis in both types of fibroblasts. Thus, our data unveil that K‐Ras and its downstream effector pathways distinctively regulate key biological processes in the development of fibrosis. Moreover, we show that K‐Ras may be a crucial mediator in TGF‐β1‐mediated effects in this cell type. J. Cell. Physiol. 231: 2224–2235, 2016.


  • Open Access

    Plasma Cardiotrophin-1 as a Marker of Hypertension and Diabetes-Induced Target Organ Damage and Cardiovascular Risk

    by Luis Gamella-Pozuelo, Isabel Fuentes-Calvo, Manuel A. Gómez-Marcos, José I. Recio-Rodriguez, Cristina Agudo-Conde, José L. Fernández-Martín, Jorge B. Cannata-Andía, José M. López-Novoa, Luis García-Ortiz, Carlos Martínez-Salgado

    The search for biomarkers of hypertension and diabetes-induced damage to multiple target organs is a priority. We analyzed the correlation between plasma cardiotrophin-1 (CT-1), a chemokine that participates in cardiovascular remodeling and organ fibrosis, and a wide range of parameters currently used to diagnose morphological and functional progressive injury in left ventricle, arteries, and kidneys of diabetic and hypertensive patients, in order to validate plasma levels of CT-1 as clinical biomarker. This is an observational study with 93 type 2-diabetic patients, 209 hypertensive patients, and 82 healthy controls in which we assessed the following parameters: plasma CT-1, basal glycaemia, systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), left ventricular hypertrophy (LVH by electrocardiographic indexes), peripheral vascular disease (by pulse wave velocity—PWV, carotid intima-media thickness—C-IMT, and ankle-brachial index—ABI), and renal impairment (by microalbuminuria, albumin/creatinine urinary ratio, plasma creatinine concentrations, and glomerular filtration rate). Hypertensive or diabetic patients have higher plasma CT-1 than control patients. CT-1 positively correlates with basal glycaemia, SBP, DBP, PP, LVH, arterial damage (increased IMT, decreased ABI), and early renal damage (microalbuminuria, elevated albumin/creatinine ratio). CT-1 also correlates with increased 10-year cardiovascular risk. Multiple linear regression analysis confirmed that CT-1 was associated with arterial injury assessed by PWV, IMT, ABI, and cardiac damage evaluated by Cornell voltage duration product. Increases in plasma CT-1 are strongly related to the intensity of several parameters associated to target organ damage supporting further investigation of its diagnostic capacity as single biomarker of cardiovascular injury and risk and, possibly, of subclinical renal damage.


  • Open Access

    Heterozygous disruption of activin receptor-like kinase 1 is associated with increased arterial pressure

    by María González-Núñez, Adela S. Riolobos, Orlando Castellano, Isabel Fuentes-Calvo, María de Los Ángeles Sevilla, Bárbara Oujo, Miguel Pericacho, Ignacio Cruz-Gonzalez, Fernando Pérez-Barriocanal, Peter Ten Dijke, et al.

    The activin receptor-like kinase 1 (ALK-1) is a type I cell-surface receptor for the transforming growth factor-β (TGF-β) family of proteins. Hypertension is related to TGF-β1, because increased TGF-β1 expression is correlated with an elevation in arterial pressure (AP) and TGF-β expression is upregulated by the renin-angiotensin-aldosterone system. The purpose of this study was to assess the role of ALK-1 in regulation of AP using Alk1 haploinsufficient mice (Alk1+/−). We observed that systolic and diastolic AP were significantly higher in Alk1+/− than in Alk1+/+ mice, and all functional and structural cardiac parameters (echocardiography and electrocardiography) were similar in both groups. Alk1+/− mice showed alterations in the circadian rhythm of AP, with higher AP than Alk1+/+ mice during most of the light period. Higher AP in Alk1+/− mice is not a result of a reduction in the NO-dependent vasodilator response or of overactivation of the peripheral renin-angiotensin system. However, intracerebroventricular administration of losartan had a hypotensive effect in Alk1+/− and not in Alk1+/+ mice. Alk1+/− mice showed a greater hypotensive response to the β-adrenergic antagonist atenolol and higher concentrations of epinephrine and norepinephrine in plasma than Alk1+/+ mice. The number of brain cholinergic neurons in the anterior basal forebrain was reduced in Alk1+/− mice. Thus, we concluded that the ALK-1 receptor is involved in the control of AP, and the high AP of Alk1+/− mice is explained mainly by the sympathetic overactivation shown by these animals, which is probably related to the decreased number of cholinergic neurons.


  • Open Access

    Effect of Angiotensin II and Small GTPase Ras Signaling Pathway Inhibition on Early Renal Changes in a Murine Model of Obstructive Nephropathy

    by Ana B. Rodríguez-Peña, Isabel Fuentes-Calvo, Neil G. Docherty, Miguel Arévalo, María T. Grande, Nélida Eleno, Fernando Pérez-Barriocanal, José M. López-Novoa

    Tubulointerstitial fibrosis is a major feature of chronic kidney disease. Unilateral ureteral obstruction (UUO) in rodents leads to the development of renal tubulointerstitial fibrosis consistent with histopathological changes observed in advanced chronic kidney disease in humans. The purpose of this study was to assess the effect of inhibiting angiotensin II receptors or Ras activation on early renal fibrotic changes induced by UUO. Animals either received angiotensin II or underwent UUO. UUO animals received either losartan, atorvastatin, and farnesyl transferase inhibitor (FTI) L-744,832, or chaetomellic acid A (ChA). Levels of activated Ras, phospho-ERK1/2, phospho-Akt, fibronectin, andα-smooth muscle actin were subsequently quantified in renal tissue by ELISA, Western blot, and/or immunohistochemistry. Our results demonstrate that administration of angiotensin II induces activation of the small GTPase Ras/Erk/Akt signaling system, suggesting an involvement of angiotensin II in the early obstruction-induced activation of renal Ras. Furthermore, upstream inhibition of Ras signalling by blocking either angiotensin AT1 type receptor or by inhibiting Ras prenylation (atorvastatin, FTI o ChA) reduced the activation of the Ras/Erk/Akt signaling system and decreased the early fibrotic response in the obstructed kidney. This study points out that pharmacological inhibition of Ras activation may hold promise as a future strategy in the prevention of renal fibrosis.


  • The small GTPase N-Ras regulates extracellular matrix synthesis, proliferation and migration in fibroblasts

    by Isabel Fuentes-Calvo, Piero Crespo, Eugenio Santos, José M. López-Novoa, Carlos Martínez-Salgado